Topical beta-blocker therapy and central nervous system side effects. A preliminary study comparing betaxolol and timolol
- PMID: 2898932
- DOI: 10.1001/archopht.1988.01060140054023
Topical beta-blocker therapy and central nervous system side effects. A preliminary study comparing betaxolol and timolol
Abstract
Topical beta-blocking agents have been associated with adverse central nervous system (CNS) effects, including depression, emotional lability, and sexual dysfunction. Two studies were done to determine if patients who develop CNS effects while using timolol maleate would improve with betaxolol hydrochloride. In one study, 18 patients with CNS symptoms during timolol therapy were switched to betaxolol. Sixteen of the 18 patients noted symptomatic improvement with betaxolol. The second study involved seven patients with CNS symptoms during timolol therapy who were entered into a double-masked cross-over study. In two patients CNS symptoms resolved with betaxolol; in three patients symptoms improved; and in one patient symptoms worsened with betaxolol. Although factors influencing beta-blocker activity in the CNS are not well understood, there may be some advantage to a selective agent.
Similar articles
-
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.Drugs Aging. 1992 May-Jun;2(3):208-21. doi: 10.2165/00002512-199202030-00005. Drugs Aging. 1992. PMID: 1351412 Review.
-
A comparison of betaxolol and timolol in open angle glaucoma and ocular hypertension.Acta Ophthalmol (Copenh). 1988 Apr;66(2):180-6. doi: 10.1111/j.1755-3768.1988.tb04008.x. Acta Ophthalmol (Copenh). 1988. PMID: 2898859 Clinical Trial.
-
Changing therapy from timolol to betaxolol. Effect on intraocular pressure in selected patients with glaucoma. Timolol-Betaxolol Study Group.Arch Ophthalmol. 1989 Sep;107(9):1303-7. doi: 10.1001/archopht.1989.01070020373038. Arch Ophthalmol. 1989. PMID: 2571326 Clinical Trial.
-
Betaxolol vs timolol. A six-month double-blind comparison.Arch Ophthalmol. 1986 Jan;104(1):46-8. doi: 10.1001/archopht.1986.01050130056019. Arch Ophthalmol. 1986. PMID: 3510612 Clinical Trial.
-
Comparison of ophthalmic beta-blocking agents.Clin Pharm. 1987 Jun;6(6):451-63. Clin Pharm. 1987. PMID: 2891463 Review.
Cited by
-
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.Drugs Aging. 1992 May-Jun;2(3):208-21. doi: 10.2165/00002512-199202030-00005. Drugs Aging. 1992. PMID: 1351412 Review.
-
Management of glaucoma: focus on pharmacological therapy.Drugs Aging. 2005;22(1):1-21. doi: 10.2165/00002512-200522010-00001. Drugs Aging. 2005. PMID: 15663346 Review.
-
Changes in depressive status associated with topical beta-blockers.Int Ophthalmol. 1992 Sep;16(4-5):331-5. doi: 10.1007/BF00917986. Int Ophthalmol. 1992. PMID: 1428568 Clinical Trial.
-
Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension.Drugs. 1990 Jul;40(1):75-90. doi: 10.2165/00003495-199040010-00005. Drugs. 1990. PMID: 2202584 Review.
-
Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems.AAPS J. 2005 Dec 7;7(4):E820-33. doi: 10.1208/aapsj070479. AAPS J. 2005. PMID: 16594634 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical